NCT06906991 (FIBROWALK+UP) is a NA clinical trial of FIBROWALK in Fibromyalgia (FM), sponsored by Hospital Universitari Vall d'Hebron Research Institute.

Who is sponsoring NCT06906991?

NCT06906991 is sponsored by Hospital Universitari Vall d'Hebron Research Institute.

What drugs are being tested in NCT06906991?

Interventions in NCT06906991: FIBROWALK, Unified Protocol.

What condition does NCT06906991 study?

NCT06906991 studies Fibromyalgia (FM).

Is NCT06906991 still recruiting?

NCT06906991 is currently not yet recruiting. Last updated 2 April 2025.

Last reviewed 2025-04-02 · How we verify

NCT06906991: FIBROWALK+UP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicomponent FIBROWALK Therapy Plus Unified Protocol for Emotional Regulation in Individuals With Fibromyalgia

Not yet recruiting NA Last updated 2 April 2025

What this trial tests

NA trial testing FIBROWALK in Fibromyalgia (FM) in 182 participants. Not yet recruiting.

Timeline

15 May 2025

Primary endpoint
1 February 2026

1 June 2026

Quick facts

Lead sponsor	Hospital Universitari Vall d'Hebron Research Institute
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	182
Start date	15 May 2025
Primary completion	1 February 2026
Estimated completion	1 June 2026
Sites	1 location across Spain

Drugs / interventions tested

FIBROWALK
Unified Protocol

Conditions studied

Fibromyalgia (FM) — all drugs for Fibromyalgia (FM) →

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

18 and older, any sex, with Fibromyalgia (FM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction. Although the FIBROWALK multicomponent program improves physical functionality and pain, its impact on emotional regulation remains limited. This study aims to integrate the Unified Protocol (UP), a cognitive-behavioral therapy (CBT) approach, to enhance emotional and physical distress tolerance in fibromyalgia patients and explore participants' satisfaction, difficulties, and barriers to treatment. This study investigates the efficacy of integrating the Unified Protocol (UP), a transdiagnostic intervention based on CBT, with the multicomponent FIBROWALK therapy for individuals with fibromyalgia. The trial seeks to enhance emotional regulation, reduce anxiety and depression, and improve quality of life. Additionally, it will gather qualitative feedback from participants to identify challenges, barriers, and potential improvements to the therapeutic intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fibromyalgia (FM)

Currently open trials in the same condition.

NCT07361328 — Personalized Ultrasonic Brain Stimulation for Fibromyalgia · NA · recruiting
NCT07356206 — Between Paws and Affections - Impact of Dog-Assisted Therapy in Fibromyalgia Patients · NA · active not recruiting
NCT07282392 — Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET) · NA · recruiting
NCT06813352 — Analysis of Facial Expressions for Pain Recognition in Fibromyalgia: Using Artificial Intelligence and Biomarkers · recruiting
NCT07074275 — Chronic Fibromyalgia Pain, Lifestyle Factors, and Inflammation · active not recruiting

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06906991 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06906991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing